Outcome of Board Meeting

Touching Lives over Date: 4th August, 2026 I VI The Manager, The Manager, Department of Corporate Services, Listing Department, BSE Limited National Stock Exchange of India Ltd. P. J. Towers, DalaI Street, 'Exchange Plaza’, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 533573 NSE Symbol: APLLTD Dear Sir / Madam, Sub: Outcome of Board Meeting held on 4th August, 2026 With reference to the captioned subject, we hereby inform the stock exchanges that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today inter-alia has approved the Consolidated and Standalone Unaudited Financial Results along with the Limited Review Report issued by the Statutory Auditors of the Company for the quarter ended 30th June, 2026. The time of commencement of Board Meeting was 12:00 noon and the time of conclusion was 1:55 p.m. We request you to kindly take the same on record. Thanking you, Yours faithfully, For Alembic Pharmaceuticals Limited araf VADO Company Secretary 00 Encl.: A/a. ALEMBIC PHARMACEUTICALS LIMITED REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 WebsIte : www.alembIGpharmaceutIcals.com ' E-maII : alemblc@alembic.co.in ' CIN: L24230GJ2010PLC061123 ALEMBIC P11ARMACEUTICAL$ LIMI rED CIN :L24230GJ2010PLC061 123 Regd.Office: Alembic Road, Vadodara - 390 003 Tel : 0265 6637000 Touching Lives over i(’ C) years Email : apI.investors@alembic.co.in Website : www.alembicpharmaceuticals.com .Statement of Consolidated Unaudited Financial Results for the quarter et'ded 30th June, 2026 Rs. in Crores Quarter Ended Year Ended Particulars 30.06.2026 31.03.2026 30.06.2025 31.03.2026 (Unaudited) (Audited) (Unaudited) (Audited} 1= Revenue from Operations 2, 149,77 1,847.72 1.710.72 7, 344.90 2 Other Income 14.93 25.50 6.50 54.41 3 Total Income 2, 164.70 1,873.22 1,717.22 7.399.31 4 Expenses (a) Cost of Materials consumed 517.30 404.24 431.27 1, 747.38 Ib) Purchase of stock-in-trade t 20.50 129.79 109. 16 508.88 (c)' Changes in Inventories of finished goods, Stock in trade and WIP (17,72) (1.88) ( 133.02) (271.81) (d) Employee benefits expense 473.94 438.91 422.77 1,731.93 (e) Finance Costs 27.61 22.56 23.52 93863 (f) Depreciation & Amortizatlon Expense 97.71 88.59 73.77 318.55 (g) Other Expenses 723.89 648.74 599.19 2,510.06 Total Expenses 1,943.23 1, 730.94 1.526.67 6,638.61 Profit before Share of Profit / (Loss) of Associates and Joint S 221.47 142.28 190.55 760.69 Ventures 6 Share of Profit / (Loss) of Associates & Joint Venture's 0.39 1.11 (0.45) ,). 24 7 Profit Before Exceptional Item and Tax 221.86 143.38 190. 10 760.94 8 Exceptional Item - Refer Note No. 3 (24.76) (66.99) 9 Profit Before Tax 221.86 1 18.62 190. 10 693695 IG 13x Expense (i) Current Tax 44.35 31.30 22.22 127.60 (ii) Deferred Tax 5.15 ( 114.21) 14.26 (104.48) It PI oat for the Period before non-controlling Interests 172.36 201.53 153.63 670.83 12 1 Non-controlling interests 0.71 1.17 0.75 3.94 13 i Profit for the Period after non-controlling interests 173.07 202.70 154.38 674.77 14 i Other Comprehensive Income A Ii) Items that wil1 not be reclassified to profit / (loss) (e_49) (1.96) (0.47) (6.96) (ii) Jncome tax relating to items that will not be reclassified to profit / 0.12 0.06 0.08 0.93 ~' ’ (less) B fi) Items that will be reclassifIed to profit / (loss) 3.14 13.45 1.10 30.89 {0.49 ) (Ii) Ira:: re tax relating to items that will be reclassified to pronE / Total Other Comprehensive Income (A+B) 2.28 1 11.54 0.71 24.86 15 Total Comprehensive Income for the period (11+ 14) 174.63 213.07 i54.33 695.69 Attributable to: Non 'controlling interests (0.70) (1.47) (0.76) (4.41) - Owners of the Company !75.33 214.54 155.09 700.09 JC Earnings per share - .Bgsjc & Di!'Jted (in Rs.) 8.80 If , 31 7.85 1'/’ Pad up Equi'iv Share Capital (Face ValIIe of Rs 2/- each) S\\ 39,31 39.31 39.31 39.31 i ,' U I L_. _ Other Equity .SS L_,__,_._J 5,635.50 Notes : The above consolidated results have been recommended by the Audit Committee and approved by the Board of Directors of the Company. The results have been subjected t) r 'vle-v by the st3tutory auditors of the Company. The report of the statutory auditors is unqualified. 2 The Company is engaged in'Philrmaceuticals bu.;ness only and therefore, there is only one reportable segMent. 3 Exceptional items for the quarter hnd year ende J 31st March 2026 comprised (i) Rs. 6.41 crore for the q iarter and Rs. 48.64 crore for the year relating to employee benefit obligations arising from the revised definition of wages under the Labour Codes, and (ii) a write-down of Rs. 18.35 crore on assets of'the Sikkim manufacturing facility classified as held for sale under Ind AS 105. 4 During the quarter ended 31s1 March 2026, consequent to the Finance Act amendment, the Company reassessed deferred tax assets and tax credits, and the resulting impact has been recognised as a credit in the Statement of Profit and Loss C Disclosures as per Regulation 52(4) of the SEBI (Listing ObIIgations and Disclosure Requirements) Regulations, 2015 as applicable and additional informations are given hereunder: Sr. Quarter Ended Year Ended No 1P articulars 30.06.2026 31.03.2026 1 30.06.2025 31.03.2026 a Debt-EquitY Ratio (in times) 0.28 o.24 o.22 0.24 Debt / Net Worth [Debt : Total Debt ( Short te,-m + Long term) Net worth : Share Capital + Other Equity] b Debt Service Coverage Ratio (in times) 7.63 5.11 9.08 6.91 (Profit before tax+interest) / (Interest + schedule principal repayments of Long term debt) Annualised C Interest Service Coverage Ratio (in times) 9.04 6.26 9.08 8.41 (Profit before tax+interest)/ Intere=t d Net Worth (Rs. in Crores) 5,856.21 Sr 680.88 5,349.08 5,680.88 (Equity capital + Other Equity excluding fair value change on financial Instruments through OCI) e Current Ratio (in times) 1.69 1.75 1.73 1.75 Current Asset / Current Liabilities f Long Term Debt to working capital (in times) 0.06 0.07 0.07 Long Term Borrowings (incl. Current Maturities)/ (Current Assets - Current Liabilities) a Bad Debts to Accounts Receivable RatIO {%) 0.04(Yo o.04cYo C).07n4) Bad Debts / Accounts Receivable h Current Liability Ratio (in times) 0.85 0.84 0.94 0.84 Current Liabilities / Total Liabilities I ITotal Debts to Total Assets (in times) 0.18 0.16 0.16 0.16 (Long term Borrowings + Short Term Borrowings+ Lease liability)/ Total Assets !j Debtors Turnover Ratio (in times) 5.20 5.08 5.32 5.05 (Value of Sales and Service / Average Debtor) Annualised k Inventory Turnover (in times) 5.03 4.70 4.58 4,67 (Sale of products / Average WIF, FG and Stock in trade Inventory) Annualised I Operating Margin (%) 16.180/o 13.840/o 16.84%) 16 . 03 qb EBITDA (before Exceptional iterns)/ Revenue from Operations m i Net Profit Margin (%) 8.050/o 10.97Cf’Cl 9.02(Yo 9 . i90/b (Net Profit after taxes and share of Profit/(1_oss) of Associates and Joint Ventures)/ Revenue from Operations For Alembic Pharmaceuticals Limited 'Vj,D Place : Murnbai Chirayu Amin Date . 4th August,2026 Chairman ’/;s'it ug a+ ',bww.al.,,nlbicpharmaceuti':aIs.cor. I ALEMBIC PHARMACEUTICALS LIMITED CIN :L24230GJ2010PLC06r 123 Regd.Office: Alembic Road, Vadodara - 390 003 i(’-T Tel : 0265 6637000 . ' v' Touching Lives over ) Email : apI.investors@alembic.co.in years Website : www.alembicpharmaceuticalSIcom Statement of Standalone Unaudited Financial Results for the quarter ended 30th June, 2026 Rs, in Crores Quarter Ended Year Ended Particulars 30.06.2026 31.03.2026 30.06.2025 31.03.2026 (Unaudited ) (Audited) (Unaudited) ( Audit M ) I Revenue from Operations 1,868.06 1,718.74 1,494. 17 6,651 38 2 Other Income 14.04 25.88 7.79 55.90 3 Total Income 1,882.10 1,744.62 1,501.96 6, 197.28 4 Expenses (a) Cost of Materials consumed 517.30 404.24 431.27 i,747.38 (b) Purchase of stock-in-trade 119.92 94.37 97.50 394 . 57 (82.24) 16.32 _ (111.50) (121.15) (c) =Tges in Inventories o llnishe goo Sr Stoc ( in tra e an (d) Enl,>loyee beneRts expense 416.46 407.03 396.40 [Showing first 8,000 characters — download PDF for full document]